Clinical Trial Update: Dysport for the Treatment of OMD [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update reporting results from a Phase 1/2 study of Dysport (abobotulinumtoxinA) for oromandibular dystonia and tardive dystonia; Emory University…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oromandibular Dystonia
• Tardive Dystonia

Drugs mentioned

• Dysport (abobotulinumtoxinA)

Snippet

Sponsor: Emory University | Conditions: Oral Dystonia, Tardive Dystonia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2017-11-17